ChinaDaily Briefs

Daily Brief China: Hygon Information Technology C, Tencent, Yankuang Energy Group, Auntea Jenny (Shanghai) Industrial, Hutchmed China Ltd and more

In today’s briefing:

  • Offshore China ETFs Rebalance Preview: Big Price Moves Could Lead to Four Changes
  • Tencent (0700.HK): Revisiting Wechat Channels
  • FXI Rebalance Preview: Three Potential Changes as Big Moves Unfold
  • Auntea Jenny (Shanghai) Industrial Pre-IPO Tearsheet
  • Hutchmed China Ltd (13.HK/​​HCM.US) – 2023 Results Preview and Catalysts in 2024



Tencent (0700.HK): Revisiting Wechat Channels

By Eric Chen

  • One year ago, we published a note valuing Wechat Channels at US$29 billion by applying 25xPE to RMB8 billion net profit out of RMB37 billion revenue by 2024.
  • Fast forward to today, the platform’s priority has been further elevated by Tencent management in its attempt to pursue high quality growth.
  • We review our thesis on Wechat Channels based on recent channel checks and now believe that the platform could represent ~35% of Tencent’s total incremental profit from 2024 to 2026. 

FXI Rebalance Preview: Three Potential Changes as Big Moves Unfold

By Brian Freitas


Auntea Jenny (Shanghai) Industrial Pre-IPO Tearsheet

By Clarence Chu

  • Auntea Jenny (Shanghai) Industrial (AJI HK) is looking to raise US$300m in its upcoming Hong Kong IPO. The bookrunners on the deal are CITIC Securities, Haitong, and DFZQ.
  • Auntea Jenny (Shanghai) Industrial (Auntea) is a freshly-made beverage producer.
  • As per CIC, the firm operates the fourth largest network of freshly-made tea shops in China as of Sept 23, with an extensive reach into the lower-tier markets

Hutchmed China Ltd (13.HK/​​HCM.US) – 2023 Results Preview and Catalysts in 2024

By Xinyao (Criss) Wang

  • HUTCHMED’s 2023 results are relatively certain. Fruquintinib had a strong start after obtaining approval in the US, with sales of about US$13-15 million in just more than a month.
  • Oncology/Immunology consolidated revenue would be in line with management’s performance guidance (US$450 to US$550 million) in 2023. There are promising data readout/NDA submission this year, which would be potential catalysts.
  • HUTCHMED has sufficient cashflow and does not require external financing. From 2024 to 2026, it will enter a period of accelerated growth in product revenue. Breakeven is achievable in 2025.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars